Renu Gupta
Directeur/Membre du Conseil chez Aim At Melanoma Foundation
Profil
Renu Gupta is currently the Director at Aim At Melanoma Foundation and a Founding Member-Industrial Management at Harvard Medical School.
Previously, she held positions such as Director at Insmed Ltd., Independent Director at Corbus Pharmaceuticals Holdings, Inc., Executive Director at Breath Therapeutics GmbH, Senior Vice President-Development at Agenus, Inc., Chief Medical Officer & Executive VP-Development at Insmed, Inc., Adjunct Assistant Professor at the University of Pennsylvania, Chief Medical Officer & EVP-Development at Transave, Inc., and VP, Head-US Clinical Research & Development at Novartis Pharmaceuticals Corp.
Dr. Gupta obtained her undergraduate and doctorate degrees from the University of Zambia.
Postes actifs de Renu Gupta
| Sociétés | Poste | Début |
|---|---|---|
| Harvard Medical School | Corporate Officer/Principal | 20/01/2011 |
| Aim At Melanoma Foundation | Directeur/Membre du Conseil | 20/01/2011 |
Anciens postes connus de Renu Gupta
| Sociétés | Poste | Fin |
|---|---|---|
| INSMED INCORPORATED | Directeur Technique/Scientifique/R&D | 02/04/2014 |
Insmed Ltd.
 Insmed Ltd. Pharmaceuticals: MajorHealth Technology Insmed Ltd. develops and manufactures pharmaceutical products for the treatment of lung diseases. Its products are used for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. The company is located in London, the United Kingdom. | Directeur/Membre du Conseil | 01/05/2008 |
| AGENUS INC. | Corporate Officer/Principal | 01/08/2006 |
| University of Pennsylvania | Corporate Officer/Principal | 01/01/1997 |
Breath Therapeutics GmbH
 Breath Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breath Therapeutics GmbH is a clinical stage biopharmaceutical company, which engages in the development of inhaled therapeutics for respiratory diseases. It offers drug device platform, which consists of liposomal drug-aerosol formulations and cutting-edge inhalation technology. The company was founded by Jens Stegemann, Gerhard Boerner, Oliver Denk, and Anne Burger in 2016 and is headquartered in Munchen, Germany. | Directeur/Membre du Conseil | - |
Formation de Renu Gupta
| University of Zambia | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AGENUS INC. | Health Technology |
| INSMED INCORPORATED | Health Technology |
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Transave, Inc.
 Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Insmed Ltd.
Insmed Ltd. Pharmaceuticals: MajorHealth Technology Insmed Ltd. develops and manufactures pharmaceutical products for the treatment of lung diseases. Its products are used for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. The company is located in London, the United Kingdom. | Health Technology |
| Aim At Melanoma Foundation | |
Breath Therapeutics GmbH
Breath Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breath Therapeutics GmbH is a clinical stage biopharmaceutical company, which engages in the development of inhaled therapeutics for respiratory diseases. It offers drug device platform, which consists of liposomal drug-aerosol formulations and cutting-edge inhalation technology. The company was founded by Jens Stegemann, Gerhard Boerner, Oliver Denk, and Anne Burger in 2016 and is headquartered in Munchen, Germany. | Health Technology |